Experiments in the current study confirmed that the oral administration of the TrK inhibitor larotrectinib significantly inhibited the effects of NGF on M2 macrophage levels and osteosarcoma progression; however, it is important to consider the complexity of the in vivo tumor microenvironment. This evidence concerns the gene NTRK1 and neoplasm.